| First Author | Pastor-Fernández A | Year | 2023 |
| Journal | Aging Cell | Volume | 22 |
| Issue | 3 | Pages | e13771 |
| PubMed ID | 36704839 | Mgi Jnum | J:336010 |
| Mgi Id | MGI:7445029 | Doi | 10.1111/acel.13771 |
| Citation | Pastor-Fernandez A, et al. (2023) Treatment with the senolytics dasatinib/quercetin reduces SARS-CoV-2-related mortality in mice. Aging Cell 22(3):e13771 |
| abstractText | The enormous societal impact of the ongoing COVID-19 pandemic has been particularly harsh for some social groups, such as the elderly. Recently, it has been suggested that senescent cells could play a central role in pathogenesis by exacerbating the pro-inflammatory immune response against SARS-CoV-2. Therefore, the selective clearance of senescent cells by senolytic drugs may be useful as a therapy to ameliorate the symptoms of COVID-19 in some cases. Using the established COVID-19 murine model K18-hACE2, we demonstrated that a combination of the senolytics dasatinib and quercetin (D/Q) significantly reduced SARS-CoV-2-related mortality, delayed its onset, and reduced the number of other clinical symptoms. The increase in senescent markers that we detected in the lungs in response to SARS-CoV-2 may be related to the post-COVID-19 sequelae described to date. These results place senescent cells as central targets for the treatment of COVID-19, and make D/Q a new and promising therapeutic tool. |
